pandemic influenza vaccine (H5N1 strain NIBRG-14)

BIOLOGICAL2 trials

Sponsors

Sinovac Biotech Co., Ltd

Conditions

Pandemic InfluenzaPandemic Influenza VaccinePrevention

Phase 1

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

CompletedNCT00660257

Sinovac Biotech Co., LtdPandemic Influenza, Pandemic Influenza Vaccine, Prevention

Start: 2007-01-31End: 2008-03-31Updated: 2008-04-17

Phase 2

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

CompletedNCT00535665

Sinovac Biotech Co., LtdPandemic Influenza, Prevention

Start: 2007-09-30End: 2007-11-30Updated: 2007-11-09

Related Papers

Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1

Nature Communications2025-07-015 citations

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

2009-04-0133 citations